Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRGXNASDAQ:IMNMNYSE:NUVBNASDAQ:PHAR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRGXCARGO Therapeutics$4.39-2.0%$4.31$3.00▼$25.45$202.42M0.31572,772 shs391,053 shsIMNMImmunome$9.20-6.0%$8.22$5.15▼$16.81$800.51M1.94918,004 shs1.26 million shsNUVBNuvation Bio$1.73-4.7%$2.15$1.54▼$3.97$586.95M1.372.64 million shs8.93 million shsPHARPharming Group$10.87-6.0%$9.63$6.65▼$12.61$739.57M0.026,213 shs3,787 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRGXCARGO Therapeutics0.00%-7.58%+6.55%+6.81%-73.74%IMNMImmunome0.00%+0.77%+14.14%+1.77%-38.34%NUVBNuvation Bio0.00%-30.16%-23.50%-17.66%-42.88%PHARPharming Group0.00%-8.96%+15.27%+22.28%+26.41%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRGXCARGO Therapeutics2.3824 of 5 stars2.90.00.00.03.31.71.3IMNMImmunome1.6163 of 5 stars3.50.00.00.02.32.50.0NUVBNuvation Bio2.9499 of 5 stars3.60.00.00.03.05.00.6PHARPharming Group2.1655 of 5 stars3.53.00.00.02.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRGXCARGO Therapeutics 1.86Reduce$15.00241.69% UpsideIMNMImmunome 3.00Buy$23.33153.62% UpsideNUVBNuvation Bio 3.17Buy$7.83354.11% UpsidePHARPharming Group 3.00Buy$30.00175.96% UpsideCurrent Analyst Ratings BreakdownLatest CRGX, NUVB, PHAR, and IMNM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025NUVBNuvation BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$5.006/2/2025NUVBNuvation BioJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$6.005/15/2025NUVBNuvation BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$5.00 ➝ $5.005/13/2025IMNMImmunomeWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$33.00 ➝ $21.004/23/2025NUVBNuvation BioCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform4/23/2025NUVBNuvation BioCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMkt Outperform$6.004/23/2025NUVBNuvation BioJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Outperform$6.004/2/2025IMNMImmunomeLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$23.003/27/2025NUVBNuvation BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$5.003/20/2025IMNMImmunomeWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$33.00 ➝ $33.003/20/2025IMNMImmunomeStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$30.00 ➝ $30.00(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRGXCARGO TherapeuticsN/AN/AN/AN/A$9.84 per shareN/AIMNMImmunome$10.94M73.19N/AN/A$2.77 per share3.32NUVBNuvation Bio$10.96M53.57N/AN/A$2.76 per share0.63PHARPharming Group$320.71M2.31$0.12 per share91.82$3.26 per share3.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRGXCARGO Therapeutics-$98.15M-$4.62N/AN/AN/AN/A-38.16%-33.94%8/11/2025 (Estimated)IMNMImmunome-$106.81M-$3.18N/AN/AN/A-3,014.59%-48.63%-41.62%8/11/2025 (Estimated)NUVBNuvation Bio-$75.80M-$2.35N/AN/AN/AN/A-21.89%-17.86%8/4/2025 (Estimated)PHARPharming Group-$10.55M-$0.20N/A362.37N/A-6.09%-7.65%-3.82%7/30/2025 (Estimated)Latest CRGX, NUVB, PHAR, and IMNM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025IMNMImmunome-$0.66-$0.52+$0.14-$0.52$0.46 million$2.93 million5/8/2025Q1 2025PHARPharming Group-$0.25-$0.22+$0.03-$0.22$67.74 million$79.09 million5/7/2025Q1 2025NUVBNuvation Bio-$0.16-$0.16N/A-$0.16$0.42 million$3.08 million3/19/2025Q4 2024IMNMImmunome-$0.68-$0.84-$0.16-$1.28$3.07 million$2.74 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRGXCARGO TherapeuticsN/AN/AN/AN/AN/AIMNMImmunomeN/AN/AN/AN/AN/ANUVBNuvation BioN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRGXCARGO TherapeuticsN/A18.9418.95IMNMImmunomeN/A6.176.17NUVBNuvation BioN/A9.579.57PHARPharming Group0.413.532.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRGXCARGO Therapeutics93.16%IMNMImmunome44.58%NUVBNuvation Bio61.67%PHARPharming Group0.03%Insider OwnershipCompanyInsider OwnershipCRGXCARGO Therapeutics2.92%IMNMImmunome8.60%NUVBNuvation Bio29.93%PHARPharming Group2.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRGXCARGO Therapeutics11646.11 million45.39 millionN/AIMNMImmunome4087.01 million72.92 millionOptionableNUVBNuvation Bio60340.26 million319.50 millionOptionablePHARPharming Group28068.03 million66.62 millionNot OptionableCRGX, NUVB, PHAR, and IMNM HeadlinesRecent News About These CompaniesShort Interest in Pharming Group (NASDAQ:PHAR) Expands By 169.2%June 13 at 7:24 PM | marketbeat.comEuropean Penny Stocks Under €200M Market Cap To WatchJune 13 at 10:55 AM | uk.finance.yahoo.comPharming Group (NASDAQ:PHAR) Trading 3.9% Higher - Here's What HappenedJune 12, 2025 | marketbeat.comPharming Group reports on results of the 2025 Annual General Meeting of ShareholdersJune 11, 2025 | finance.yahoo.comPharming Group Announces Key Board Appointments and Approvals at 2025 AGMJune 11, 2025 | tipranks.comPharming Group (NASDAQ:PHAR) Sees Large Volume Increase - Here's WhyJune 11, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Shares Down 4.6% - Here's What HappenedJune 10, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Trading Up 6.7% - Here's WhyJune 8, 2025 | americanbankingnews.comPharming Group (NASDAQ:PHAR) Stock Price Up 6.7% - Here's What HappenedJune 6, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Shares Gap Down - Should You Sell?June 5, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Shares Gap Up - Here's What HappenedJune 4, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Reaches New 1-Year High - What's Next?June 3, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Sees Large Decline in Short InterestJune 3, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Stock Price Up 10.1% - Here's What HappenedMay 31, 2025 | marketbeat.comPharming Group to participate in June investor conferencesMay 28, 2025 | finance.yahoo.comPharming Group to participate in June investor conferences | PHARM Stock NewsMay 28, 2025 | gurufocus.comPharming Group First Quarter 2025 Earnings: US$0.022 loss per share (vs US$0.019 loss in 1Q 2024)May 10, 2025 | finance.yahoo.comPharming Group N.V. (PHAR) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comPharming Group N.V. 2025 Q1 - Results - Earnings Call PresentationMay 9, 2025 | seekingalpha.comPharming Group’s Strong Financial Performance and Strategic Growth Drive Buy RatingMay 8, 2025 | tipranks.comPharming Group N.V.: Pharming Group reports first quarter 2025 financial results and provides business updateMay 8, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueThese Are the Only 6 Stock Stocks in NVIDIA's 13F PortfolioBy Leo Miller | May 22, 2025View These Are the Only 6 Stock Stocks in NVIDIA's 13F PortfolioEli Lilly : A Breakout Biotech Powerhouse With Room to RunBy Jeffrey Neal Johnson | May 29, 2025View Eli Lilly : A Breakout Biotech Powerhouse With Room to RunAnalysts Can't Get Enough of These Little-Known Biopharma StocksBy Nathan Reiff | June 12, 2025View Analysts Can't Get Enough of These Little-Known Biopharma StocksCRGX, NUVB, PHAR, and IMNM Company DescriptionsCARGO Therapeutics NASDAQ:CRGX$4.39 -0.09 (-2.01%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$4.39 0.00 (0.00%) As of 06/13/2025 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.Immunome NASDAQ:IMNM$9.20 -0.59 (-6.03%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$9.22 +0.02 (+0.16%) As of 04:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.Nuvation Bio NYSE:NUVB$1.72 -0.09 (-4.70%) Closing price 06/13/2025 03:59 PM EasternExtended Trading$1.80 +0.08 (+4.35%) As of 05:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.Pharming Group NASDAQ:PHAR$10.87 -0.69 (-5.96%) Closing price 06/13/2025 03:55 PM EasternExtended Trading$11.29 +0.41 (+3.82%) As of 04:25 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
